MMMaria Manali

Maria Manali

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria Manali has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Robust Adaptive Immunity to MPXV in Older People Who Received Childhood Vaccinia Vaccination

    by Chris Davis, Jianmin Zuo, Rachel Bruton, Marie Hodges, Tom Roberts, Maria Manali, Paula Olmo, Brian Willett, Paul Moss, Helen Parry

    Monkeypox virus (MPXV) is a zoonotic Orthopoxvirus responsible for Monkeypox (Mpox), historically associated with sporadic zoonotic transmission but increasingly characterised by sustained human-to-human spread. While vaccinia-based vaccination is known to confer cross-protection against MPXV, the durability of such immunity over a human lifetime remains incompletely characterised. Here, we assessed humoral and cellular immune responses to MPXV in octogenarians and nonagenarians vaccinated against smallpox during childhood. Twenty-three adults aged 79–94 years (median 83), who self-reported childhood vaccinia vaccination between 1925 and 1940, were recruited. MPXV-specific antibody responses were evaluated using ELISA, targeting homologous vaccinia and MPXV proteins, and live-virus neutralisation assays. Cellular immunity was assessed by IFN-γ ELISpot following stimulation with peptide pools derived from highly conserved vaccinia antigens. Responses were also obtained from younger, recently MVA–BN-vaccinated and unvaccinated control donors. All historically vaccinated participants exhibited MPXV-reactive IgG responses, with antibody binding and neutralisation levels comparable to recently vaccinated individuals. Functional neutralising activity against MPXV was detected in all donors, with ≥50% neutralisation observed in 78% of participants. Antibody concentrations correlated strongly with neutralisation capacity. T-cell responses were detectable in all historically vaccinated donors, most prominently against the major core protein A10L, although reduced magnitudes were observed in participants over 90 years of age. No MPXV-specific humoral or cellular responses were detected in unvaccinated controls. These findings demonstrate that childhood vaccinia vaccination induces durable humoral and cellular immunity against MPXV persisting for over seven decades. Historical smallpox vaccination status may therefore remain a relevant determinant of protection against Mpox.


  • Open Access

    Post-pandemic changes in population immunity have reduced the likelihood of emergence of zoonotic coronaviruses

    by Ryan M Imrie, Laura A Bissett, Savitha Raveendran, Maria Manali, Julien A R Amat, Laura Mojsiejczuk, Nicola Logan, Andrew Park, Marc Baguelin, Mafalda Viana, et al.

    Infections caused by endemic viruses, and the vaccines used to control them, often provide cross-protection against related viruses. This cross-protection has the potential to alter the transmission dynamics and likelihood of emergence of novel zoonotic viruses with pandemic potential. Here, we investigate how changes in population immunity after the COVID-19 pandemic have impacted the likelihood of emergence of a novel sarbecovirus, termed SARS-CoV-X. We show that sera from patients with different COVID-19 immunological histories possess cross-neutralising antibodies against the spike (S) protein of multiple zoonotic sarbecoviruses. Mathematical simulations using these viruses show a significant reduction in their likelihood of emergence in populations with current levels of SARS-CoV-2 natural and vaccine-derived immunity, with the outcome determined by the extent of cross-protection and the R 0 of the novel virus. We also show that preventative vaccination programs against SARS-CoV-X using currently available COVID-19 vaccines can help resist emergence even in the presence of co-circulating SARS-CoV-2. However, it was possible for a theoretical vaccine with very high specificity to SARS-CoV-2 (i.e., one which elicits very low cross-protection against SARS-CoV-X) to increase the likelihood of SARS-CoV-X emergence, due to its effects on SARS-CoV-2 prevalence and, by extension, the levels of naturally-derived cross-protection in the human population. Overall, our findings show that SARS-CoV-2 circulation and COVID-19 vaccination have generated widespread population immunity against antigenically related sarbecoviruses, and this new immunological barrier is likely to be a strong determinant of the ability of novel sarbecoviruses to emerge in humans. One-Sentence Summary: Future emergence of zoonotic coronaviruses is less likely due to post-pandemic shifts in population immunity.

  • Open Access

    Adeno-associated virus 2 infection in children with non-A-E hepatitis

    by Antonia Ho, Richard Orton, Rachel Tayler, Patawee Asamaphan, Lily Tong, Katherine Smollett, Chris Davis, Maria Manali, Sarah E. McDonald, Louisa Pollock, et al.

    Summary paragraph: An outbreak of acute hepatitis of unknown aetiology in children was first reported in Scotland in April 2022. 1 Cases aged 2 Here we report a detailed investigation of 9 early cases and 58 control subjects. Using next-generation sequencing and real-time PCR, adeno-associated virus 2 (AAV2), was detected in the plasma of 9/9 and liver of 4/4 patients but in 0/13 sera/plasma of age-matched healthy controls, 0/12 children with adenovirus (HAdV) infection and normal liver function and 0/33 children admitted to hospital with hepatitis of other aetiology. AAV2 typically requires a coinfecting ‘helper’ virus to replicate, usually HAdV or a herpesvirus. HAdV (species C and F) and human herpesvirus 6B (HHV6B) were detected in 6/9 and 3/9 affected cases, including 3/4 and 2/4 liver biopsies, respectively. The class II HLA-DRB1*04:01 allele was identified in 8/9 cases (89%), compared with a background frequency of 15.6% in Scottish blood donors, suggestive of increased susceptibility in affected cases. Acute non-A-E paediatric hepatitis is associated with the presence of AAV2 infection, which could represent a primary pathogen or a useful biomarker of recent HAdV or HHV6B infection. Population and mechanistic studies are required to explore these findings further.